Kullanma Kılavuzu
Transkript
Kullanma Kılavuzu
KAPVORM PMS ZWART à 100 % 45685-1 DIRECTIONS FOR USE: FOR INTRAOCULAR USE. FOR SINGLE USE ONLY. The syringe assembly is designed only for the injection of the PROVISC® Ophthalmic Viscosurgical Device it contains. Use of the syringe assembly for aspiration is not advised. Refrigerated PROVISC® OVD should be allowed to attain room temperature prior to use (approximately 20-40 minutes depending on quantity). BASE OF SYRINGE GREEN PLUNGER ROD SYRINGE TIP ® TIP CAP GREEN END CAP RUBBER PLUNGER Oftalmik Viskocerrahi Cihaz› 1. PEEL LID FROM BLISTER PACK UNDER ASEPTIC CONDITIONS. 2. REMOVE RUBBER TIP CAP FROM SYRINGE TIP (CAP IS ON TIGHTLY). TANIMI VE ‹ÇER‹⁄‹ PROVISC® Oftalmik Viskocerrahi Cihaz›, fizyolojik sodyum klorür fosfat tamponunda çözündürülmüfl steril, apirojen, yüksek moleküler a¤›rl›kl›, non-enflamatuvar, yüksek derecede saflaflt›r›lm›fl sodyum hiyaluronat fraksiyonudur. PROVISC® OVC en az bir 25,000 mPa.s (kopma oran› 1 sn-1, 25°C) vizkositede formüle edilmifltir. STERILE IRRIGATING SOLUTION FILLED HUB BSS® STERILE IRRIGATING SOLUTION CANNULA FILLING HUB OF PROVISC® OVD CANNULA COLORLESS CARTRIDGE 3. INJECT STERILE IRRIGATING SOLUTION INTO THE CANNULA HUB AND FILL IT TO THE TOP. PROVISC Reolojik Profili ® FULL-SIZE DETAIL 1000 100 4. EXPRESS THE AIR FROM THE TIP OF THE SYRINGE BY HOLDING THE SYRINGE BARREL WITH ONE HAND WHILE GENTLY DEPRESSING THE PLUNGER ROD WITH THE OTHER. BE CAREFUL NOT TO EXPRESS VISCOSURGICAL DEVICE ONTO THE OUTSIDE OF THE SYRINGE TIP. Viskozite (Pa.s) GREEN CAP (Sodyum Hiyaluronat) 10 1 0.1 0.01 1e-4 CANNULA (WITH COLORLESS PLASTIC CARTRIDGE STILL IN PLACE) 1e-3 1e-2 1e-1 1e+0 1e+1 1e+2 1e+3 1e+4 1e+5 Kopma oranı (s-1) 5. THREAD THE CANNULA ONTO THE SYRINGE SLEEVE IN A CONTINUOUS MOTION BY USING THE CARTRIDGE AS A WRENCH. TWIST UNTIL THE CANNULA HUB HAS TRAVELED THE FULL LENGTH OF THE THREADS AND IS FIRMLY SEATED. USE ONLY THE CANNULA PROVIDED. 6. VISUALLY INSPECT THAT THE CANNULA THREADS HAVE TRAVELED THE FULL LENGTH OF THE SYRINGE SLEEVE THREADS. 7. REMOVE PLASTIC CARTRIDGE FROM THE CANNULA IN A STRAIGHT MOTION, BEING SURE NOT TO TWIST OR UNSCREW THE CANNULA WHILE REMOVING THE CARTRIDGE. CANNULA PROVISC® OVC’in her ml’sinde aktif 10.0 mg sodyum hiyaluronat; 2.0 mg disodyum fosfat, anhidroz; 0.45 mg sodyum dihidrojen fosfat; monohidrat; 7.5 mg sodyum klorür; pH de¤erini ayarlamak için hidroklorik asit ve/veya sodyum hidroksit ve enjeksiyon için su bulunmaktad›r. PROVISC® OVC içinde kullan›lan sodyum hiyaluronat bakteriyel fermantasyondan türemifltir ve 2,500,000 Dalton ortalama molekül a¤›rl›¤›na sahiptir. PROVISC® OVC’in ozmolalitesi 310 ± 50 mOsm/kg; pH’› 7.2 ± 0.4’tür. ÖNER‹LEN KULLANIM YER‹ PROVISC® OVC, katarakt ekstraksiyonu ve göz içi lens (IOL) implantasyonu s›ras›nda ön segmentte bir göz cerrahisi yard›mc›s› olarak kullan›lmal›d›r. Oftalmik visko-elastikler, ön segment cerrahisi s›ras›nda derin bir ön kamaran›n korunmas›n› sa¤layarak kornea endoteli ve civar göz dokular›n›n daha az travmatize olmas›n› sa¤lamaktad›r. Bu malzemeler vitröz yüzeyin geri itilmesine yard›mc› olmakta ve ameliyat s›ras›nda düz bir kamara oluflmas›n› önlemektedir. KULLANILMAMASI GEREKEN DURUMLAR fiu an itibariyle önerildi¤i flekilde kullan›lmas› kofluluyla PROVISC® OVC kullan›m›na ba¤l› bilinen bir kontrendikasyon mevcut de¤ildir; bu malzemede bulunan unsurlardan herhangi birine karfl› afl›r› duyarl›l›¤› olan hastalarda dikkat edilmelidir (Bkz. Önlemler Bölümü). UYARI Kullan›m k›lavuzunda verilen talimatlar›n tamam›n› uygulamamas› veya di¤er bir kanül kullan›m› kanül ayr›lmas›na ya da ciddi bir yaralama olas›l›¤›na neden olabilir. GREEN CANNULA LOCKING RING 8. HOLD THE SYRINGE UPRIGHT. SLIP THE CANNULA LOCKING RING OVER THE CANNULA ALLOWING THE DISTAL TIP OF THE CANNULA TO PASS THROUGH THE SMALL HOLE IN THE CANNULA LOCKING RING. UYARILAR/ÖNLEMLER (a) Cerrahi giriflim s›ras›nda ön segment cerrahisi kurallar›na uyulmal›d›r. (b) Sodyum hiyaluronat ürünleriyle ameliyat sonras›nda göz içi bas›nçta art›fl olabildi¤i rapor edilmifltir. G‹B dikkatli bir flekilde izlenmeli ve önemli bir art›fl›n olmas› halinde uygun tedavi bafllat›lmal›d›r. (c) Ön kamaray› kapasitesinin üzerinde doldurmay›n›z. PROVISC® OVC’in ameliyat›n sonunda irigasyon ve/veya aspirasyon yoluyla uzaklaflt›r›lmas› tavsiye edilmektedir. Bu amaç için fl›r›nga birlefltirilmesi önerilmemektedir. (d) PROVISC® OVC içinde kullan›lan sodyum hiyaluronat patentli bir saflaflt›rma ifllemiyle mikrobik fermantasyonla elde edilmektedir. Bu materyali proteinden ar›nd›rmak için önlemler al›nm›fl ve ürün alerjenik yan›t yönünden hayvanlarda denenmifl olmakla birlikte bu cihaz duyarl› kiflilerde kullan›ld›¤›nda alerjik yan›tlar›n oluflmas›na neden olabilir. (e) Yukar›da hususlar›n yan› s›ra afla¤›daki önlemlerin de al›nmas› gerekmektedir: – Kanülleri birden fazla sefer kullanmay›n›z. – Malzemeyi ancak berraksa kullan›n›z. – Hava kabarc›¤› kalmamas›na dikkat ediniz. – Sadece ambalaj zarar görmemiflse kullan›n›z. 9. SECURE THE CANNULA BY ROTATING THE CANNULA LOCKING RING CLOCKWISE UNTIL IT STOPS AGAINST THE CANNULA HUB. ADVERS ETK‹LER (a) PROVISC® Oftalmik Viskocerrahi Cihaz› göz cerrahisi ifllemleri s›ras›nda insan gözüne enjekte edildikten sonra iyi tolere edilmektedir. Ço¤u viskoelastikte oldu¤u gibi baz› vakalarda geçici bir göz içi bas›nc› oldu¤u rapor edilmifltir. (b) Oftalmik viskoelastikler kullan›ld›¤›nda, kornea ödemi ve kornea dekompensasyonunun yan› s›ra hipopiyon ve irit benzeri ameliyat sonras› enflamatuvar reaksiyonlar geliflebildi¤i rapor edilmifltir. Bunlar›n sodyum hiyaluronat (PROVISC ® OVC) kullan›m›yla olan iliflkisi henüz belirlenmemifltir. 10. PURGE THE REMAINING AIR FROM THE SYSTEM BY HOLDING THE SYRINGE BARREL WITH ONE HAND AND GENTLY DEPRESSING THE PLUNGER ROD WITH THE OTHER UNTIL PROVISC® OVD APPEARS AT THE CANNULA TIP. SYMBOLS USED ON LABELING Symbol Symbol English Attention : See Instructions for Use Do not reuse English Sterilized Using Aseptic Processing Techniques Sterilized by Ethylene Oxide Temperature limitation. Store between 2°- 8°C. SUNUM fiEKL‹ PROVISC® OVC, 27-gauge, tek kullan›ml›k keskin olmayan uçlu kanül ve kanül kilitleme halkas› ile birlikte 0.4 ml, 0.55 ml ya da 0.85 ml olarak ambalajlarda tek kullan›ml›k cam fl›r›ngalarda sunulan steril , apirojen, tek kullan›ml›k bir oftalmik viskocerrahi cihazd›r (fizyolojik sodyum klorür fosfat tamponunda çözündürülmüfl 10 mg/ml sodyum hiyaluronat). Does not contain dry natural rubber or natural rubber latex PROVISC® OVC fl›r›ngalar› aseptik olarak doldurulmufl ve blister ambalajlarda paketlenmifltir. fi›r›ngalar›n d›fl k›s›mlar› etilen oksit yöntemiyle sterilize edilmifltir . Use by Batch Code 21 PAP © 2007, 2009, 2012 Novartis Recyclable incorrugated cardboard ÇEVKO Green Dot Manufacturer Do not use if sterile barrier is breached. Distributed by: ALCON LABORATUVARLARI T‹C. A.fi. Kavac›k Ticaret Merkezi, Rüzgarl›bahçe Mah. Kavak Sok. No:18 B-Blok Kat 1, 34805 Beykoz/STANBUL Manufacturer: Alcon Laboratories, Inc., 6201 South Freeway, Fort Worth, Texas, USA 76134-2099 Produced by: SA ALCON-COUVREUR NV, Rijksweg 14, B-2870 Puurs, Belgium Authorized EU Representative: Alcon Laboratories (UK) Ltd. Boundary Way, Hemel Hempstead, Hertfordshire, HP2 7UD, United Kingdom Dondurulmufl PROVISC® OVC'i kullan›lmadan önce oda s›cakl›¤›na gelmesini bekleyiniz (miktara göre 20-40 dakika). – Buzdolab›nda saklay›n›z (2° – 8°C, 36° – 46°F). – Dondurmay›n›z. – Ifl›k almayacak yerlerde muhafaza ediniz. Eur. Pat. No. 0 980 276 BELGIUM 45685-1 Provisc IBC 0,40 / 0,55 / 0,85 ml CE recto-verso TR AANTAL KLEUREN : 1 VC / 14.06.2012 Approval 280 x 335 / 140 x 44 mm Local Ready for sending: Graphics BESOP-00326 V4 UYGULAMALARI Katarakt Cerrahisi - IOL ‹mplantasyonu Ön kamaraya yeterli miktarda PROVISC® Oftalmik Viskocerrahi Cihaz’›n yavafl ve dikkatli bir flekilde enjekte edilmesi için bir kanül kullan›lmaktad›r. Enjeksiyon kamaraya, kristalin lens ç›kar›lmadan önce ya da sonra yap›labilir. PROVISC® OVC ayn› zamanda implantasyon cerrahisinden önce göz içi lensin yan› s›ra cerrahi aletlerinin kaplanmas›nda da kullan›labilir. Cerrahi manipülasyon s›ras›nda yitirilen s›v›y› telafi etmek için cerrahi s›ras›nda enjekte edilebilir. (bkz. Önlemler Bölümü). Affiliates as is. new proof. The undersigned: confirms that this proof contains an accurate translation of the English Corporate Standard text, and is in compliance with the registered information and the legal rules. Please also carefully check: local barcodes if any, formula, components if mentionned, shelflife if mentionned, storage conditions and trademarks. This proof is approved Signature and date: as is. as is, waiting for M.O.H. approval. (do not order component yet) Customer requests new proof. Local Final release: Graphics as is. new proof. PMS ZWART à 100 % KAPVORM KULLANIM TAL‹MATLARI: GÖZ ‹Ç‹ KULLANIMINA YÖNEL‹KT‹R. SADECE TEK KULLANIMLIKTIR. fi›r›nga düzene¤i sadece PROVISC® Oftalmik Viskocerrahi Cihaz›n›n enjekte edilmesi için tasarlanm›flt›r. fi›r›nga düzene¤inin aspirasyon için kullan›lmas› tavsiye edilmemektedir. Dondurulmufl PROVISC® OVC kullan›lmadan önce oda s›cakl›¤›na gelmesi beklenmelidir (miktara ba¤l› olarak yaklafl›k 20-40 dakika). ® Ophthalmic Viscosurgical Device (sodium hyaluronate) fiIRINGA TABANI YEfi‹L P‹STON M‹L‹ fiIRINGA UCU DESCRIPTION PROVISC® Ophthalmic Viscosurgical Device is a sterile, non-pyrogenic, high molecular weight, non-inflammatory highly purified fraction of sodium hyaluronate, dissolved in physiological sodium chloride phosphate buffer. PROVISC® OVD is formulated to a viscosity of at least 25,000 mPa.s (at shear rate of 1 sec-1, 25°C). YEfi‹L UÇ KAPA⁄I UÇ KAPA⁄I KAUÇUK P‹STON 1. BL‹STER AMBALAJIN KAPA⁄INI ASEPT‹K KOfiULLAR ALTINDA AÇINIZ. 2. fiIRINGA UCUNDAN KAUÇUK KAPA⁄I ÇIKARTINIZ. (KAPAK SIKICA KAPALIDIR). PROVISC Rheological Profile ® 1000 100 YEfi‹L KAPAK PROVISC® OVC KANÜLÜNÜN BSS® STER‹L ‹RR‹GASYON SOLÜSYONU KANÜL DOLUM KAPA⁄I RENKS‹Z KARTUfi Viscosity (Pa.s) STER‹L ‹RR‹GASYON SOLÜSYONU DOLUM KAPA⁄I TAM BOY AYRINTISI 10 1 0.1 0.01 1e-4 1e-3 1e-2 1e-1 1e+0 1e+1 1e+2 1e+3 1e+4 1e+5 Shear rate (sec-1) 3. KANÜL KAPA⁄INA STER‹L YIKAMA SOLÜSYONU ENJEKTE ED‹N VE A⁄ZINA KADAR DOLDURUN. 4. fiIRINGA GÖVDES‹N‹ B‹R EL‹N‹ZLE TUTARKEN D‹⁄ER EL‹N‹ZLE DALMA P‹STONUNU YUMUfiAKÇA BASTIRARAK fiIRINGANIN UCUNDAK‹ HAVAYI BOfiALTINIZ. fiIRINGA UCUNUN DIfi KISMINA V‹SKOELAST‹K TAfiIRMAMAYA D‹KKAT ED‹N‹Z. KANÜL (RENKS‹Z PLAST‹K KARTUfi HALA TAKILIYKEN) 5. KARTUfiU B‹R SOMUN ANAHTARI G‹B‹ KULLANARAK SÜREKL‹ B‹R HAREKETLE KANÜLÜ fiIRINGA KOLUNA V‹DALAYIN. KANÜL KAPA⁄INI V‹DALARIN SONUNA GELENE VE SIKICA OTURANA KADAR DÖNDÜRÜN. SADECE B‹RL‹KTE VER‹LEN KANÜLÜ KULLANIN. 6. KANÜLÜN D‹fiLER‹N‹N, fiIRINGA KOLU V‹DA D‹fi‹NE TAMAMEN OTURDU⁄UNDAN EM‹N OLUN. 7. PLAST‹K KARTUfiU KANÜLDEN DÜZ B‹R HAREKETLE ÇIKARTIN VE KARTUfiU ÇIKARTIRKEN KANÜLÜ DÖNDÜRMEMEYE YA DA SÖKMEMEYE ÖZEN GÖSTER‹N. 8. fiIRINGAYI D‹K TUTUN. KANÜL K‹L‹TLEME HALKASINI KANÜLÜN ÜZER‹NE KAYDIRARAK KANÜLÜN UZAK UCUNUN KANÜL K‹L‹TLEME HALKASINDAK‹ KÜÇÜK DEL‹KTEN GEÇMES‹N‹ SA⁄LAYIN. 9. KANÜL K‹L‹TLEME HALKASINI SAAT ‹ST‹KAMET‹NDE KANÜL KAPA⁄INA YASLANANA DEK DÖNDÜREREK KANÜLÜ SAB‹TLEY‹N. 10. fiIRINGANIN GÖVDES‹N‹ B‹R EL‹N‹ZLE TUTARKEN D‹⁄ER EL‹N‹ZLE P‹STON M‹L‹NE, KANÜL UCUNDA PROVISC® OVC GÖRÜNENE DEK YUMUfiAKÇA BASTIRARAK S‹STEMDE KALAN HAVAYI BOfiALTIN. Sembol ETIKETLEMEDE KULLANILAN SEMBOLLER Açiklamasi Dikkat: Kullan›m talimatlar›na bak›n›z Tekrar kullanmay›n›z Son kullan›m tarihi Seri No Geri Kazan›labilir Karton PAP Ürün aseptik ifllem teknikleri kullan›larak sterilize edilmifltir Primer Ürün etilen oksit yöntemiyle sterilize edilmifltir. Is› k›s›tlamas›. 2°C-8°C aras›nda saklay›n›z. Kuru do¤al kauçuk ya da do¤al lateks içermez ÇEVKO Yeflil Nokta Da¤›t›c› Firma: ALCON LABORATUVARLARI T‹C. A.fi. Kavac›k Ticaret Merkezi, Rüzgarl›bahçe Mah. Kavak Sok. No:18 B-Blok Kat 1, 34805 Beykoz/STANBUL ‹malatç›: Alcon Laboratories, Inc., 6201 South Freeway, Fort Worth, Texas, ABD 76134-2099 Üretim Yeri: SA ALCON-COUVREUR NV, Rijksweg 14, B-2870 Puurs, BELÇIKA Yetkili AB Temsilcisi: Alcon Laboratories (UK) Ltd., Boundary Way, Hemel Hempstead, Hertfordshire, HP2 7UD, ‹ngiltere Eur. Pat. No. 0 980 276 ADVERSE REACTIONS (a) PROVISC® Ophthalmic Viscosurgical Device is tolerated after injection into human eyes during ophthalmic surgical procedures. As with most viscoelastics, a transient rise in intraocular pressure has been reported in some cases. (b) Postoperative inflammatory reactions such as hypopyon and iritis have been reported with the use of ophthalmic viscoelastics, as well as incidents of corneal edema and corneal decompensation. Their relationship to the use of sodium hyaluronate (PROVISC ® OVD) has not been established. APPLICATIONS Cataract Surgery - IOL Implantation A cannula is used to slowly and carefully inject a sufficient amount of PROVISC® Ophthalmic Viscosurgical Device into the anterior chamber. The injection may be performed before or after removal of the crystalline lens. PROVISC® OVD may also be used to coat surgical instruments and the intraocular lens prior to implantation. Additional PROVISC® OVD can be injected during surgery to replace any PROVISC® OVD lost during surgical manipulation (see Precautions section). HOW SUPPLIED , non-pyrogenic, single use ophthalmic viscosurgical device (sodium hyaluronate, PROVISC® OVD is a sterile 10 mg/ml, dissolved in physiological sodium chloride phosphate buffer) supplied in disposable glass syringes delivering 0.4 ml, 0.55 ml or 0.85 ml packaged with a sterile 27-gauge, disposable blunt-tip cannula and cannula locking ring. PROVISC® OVD syringes are aseptically filled and packaged in blister packs. The exterior of the syringe is sterilized by ethylene oxide. Refrigerated PROVISC® OVD should be allowed to attain room temperature prior to use (approximately 20-40 minutes depending on quantity). – Store in refrigerator (2°– 8°C, 36°– 46°F). – Protect from freezing. – Protect from light. 06-2012 should be deleted. BS/RA_2012-Sep-11 45685-1 BELGIUM 45685-1 Provisc IBC 0,40 / 0,55 / 0,85 ml CE recto-verso TR AANTAL KLEUREN : 1 VC / 14.06.2012 Approval 280 x 335 / 140 x 44 mm Local Ready for sending: Graphics BESOP-00326 V4 Açiklamasi E¤er steril koruma zedelenmiflse kullanmay›n›z. Üretici © 2007, 2009, 2012 Novartis CONTRAINDICATIONS At present there are no known contraindications to the use of PROVISC® Ophthalmic Viscosurgical Device when used as recommended; care should be used in patients with hypersensitivity to any components in this material (see Precautions section). PRECAUTIONS (a) Precautions normally associated with anterior segment surgical procedures should be observed. (b) Postoperative increases in intraocular pressure have been reported with sodium hyaluronate products. The IOP should be carefully monitored and appropriate therapy instituted if significant increases occur. (c) Do not overfill the anterior chamber. It is recommended that PROVISC® Ophthalmic Viscosurgical Device be removed by irrigation and/or aspiration at the close of surgery. Use of the syringe assembly for this purpose is not advised. (d) The sodium hyaluronate in PROVISC® OVD is obtained from microbial fermentation by a proprietary purification process. Although precautions have been taken to make this device protein-free and it has been tested in animals for allergenic response, this device, used in susceptible persons, may produce allergenic responses. (e) In addition to the above, the following precautions should be observed: – Do not reuse cannulas. – Use only if material is clear. – Avoid trapping air bubbles. – Use only if container is undamaged. YEfi‹L KANÜL K‹L‹TLEME HALKASI 21 INDICATIONS PROVISC® Ophthalmic Viscosurgical Device is indicated for use as an ophthalmic surgical aid in the anterior segment during cataract extraction and intraocular lens (IOL) implantation. Ophthalmic viscoelastics serve to maintain a deep anterior chamber during anterior segment surgery allowing reduced trauma to the corneal endothelium and surrounding ocular tissues. They help to push back the vitreous face and prevent formation of a flat chamber during surgery. WARNING Failure to follow all of the assembly instructions in "Directions for Use" or use of an alternate cannula may result in cannula detachment and the possibility of serious injury. KANÜL Sembol Each ml of PROVISC® OVD contains 10.0 mg sodium hyaluronate ; 2.0 mg disodium phosphate, anhydrous; 0.45 mg sodium dihydrogen phosphate, monohydrate ; 7.5 mg sodium chloride ; hydrochloric acid and/or sodium hydroxide to adjust pH and water for injection. The sodium hyaluronate used in PROVISC® OVD is derived from bacterial fermentation and has an average molecular weight of 2,500,000 Daltons. The osmolality of PROVISC® OVD is 310 ± 50 mOsm/kg; the pH is 7.2 ± 0.4. Affiliates as is. new proof. The undersigned: confirms that this proof contains an accurate translation of the English Corporate Standard text, and is in compliance with the registered information and the legal rules. Please also carefully check: local barcodes if any, formula, components if mentionned, shelflife if mentionned, storage conditions and trademarks. This proof is approved Signature and date: as is. as is, waiting for M.O.H. approval. (do not order component yet) Customer requests new proof. Local Final release: Graphics as is. new proof.